Nidlegy was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned.
Read Press ReleaseA majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán's service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022.
Read Press ReleaseRecardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.
Read Press ReleasePilot program brings genetic tools and education to patients searching for answers tied to their chronic medical conditions in Taiwan, Mexico, Argentina, Brazil, Turkey, and Russia
Read Press ReleaseThis is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio
Read Press ReleasePresentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.
Read Press ReleaseThe collaborative research aims to fill several gaps in the scientific understanding of the chemical composition of psychedelic psilocybin-containing mushrooms
Read Press ReleaseAgreement will enhance BenchSci's vast biomedical database to help scientists run more successful experiments while increasing discoverability of Taylor & Francis Group research
Read Press ReleaseNew digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020
Read Press ReleaseEnalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.
Read Press Release